BioNotebook: Five VC deals, three public financings, and a round of layoffs
This article was originally published in Scrip
Syros raises $53m Series B; Aileron gets $33m more for Series E; Imago closes $26.5m Series A; $20m equity investment for Xcovery; Affinivax launches with $4m; Synergy sells convertible notes; Regulus, Vanda price stock offerings; and Impax cuts 49 jobs.
You may also be interested in...
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.